A Missouri judge approved a settlement Friday allowing German pharmaceutical and agrochemical company Bayer to pay up to $7.25 billion over 21 years to resolve claims that its Roundup weed killer caused non-Hodgkin lymphoma. The agreement covers thousands of current cancer patients and people diagnosed with the disease in future years after exposure to the product.
The settlement provides a path to compensation for plaintiffs while offering Bayer a measure of financial certainty after years of costly litigation. The company has faced approximately 200,000 Roundup-related claims since acquiring Monsanto in 2018, including lawsuits from agricultural workers and homeowners who used the herbicide on lawns and gardens.
Under the agreement, eligible participants could receive average payments ranging from $10,000 to $165,000. Compensation will depend on factors including the claimant’s age at diagnosis, the severity of the illness and the extent of exposure. The settlement also includes $600 million for attorneys’ fees.
St. Louis Circuit Judge Timothy Boyer determined that the settlement’s compensation was “fair and adequate,” describing the total amount as one of the largest in mass tort personal-injury cases. He also warned that Bayer could have faced bankruptcy if the agreement had been rejected.
Bayer Chief Executive Bill Anderson called the approval a major step in the company’s effort to reduce the risks posed by current and future Roundup litigation. The company continues to deny that glyphosate, Roundup’s active ingredient, causes cancer.
The settlement comes as the legal landscape for Roundup claims has shifted. In June, the U.S. Supreme Court ruled that Bayer could not be sued in state courts over claims that the company failed to include a cancer warning on Roundup labels, because federal regulations do not require such a warning and prohibit states from imposing additional labeling requirements.
The ruling weakened a central argument used by many plaintiffs and increased the uncertainty surrounding future lawsuits. Some attorneys representing cancer patients have criticized the settlement’s payout amounts and restrictions, but others have argued that guaranteed compensation is preferable to the possibility of receiving nothing after the Supreme Court decision.
Roundup was introduced by Monsanto in 1974 and became one of the most widely used herbicides in the world. Farmers commonly use glyphosate with genetically modified crops engineered to withstand the chemical, allowing them to control weeds while reducing the need for tilling. The product has also been widely used by homeowners.
Scientific assessments of glyphosate remain disputed. The World Health Organization’s International Agency for Research on Cancer classified it as “probably carcinogenic” in 2015, while the U.S. Environmental Protection Agency has concluded that glyphosate is not likely to cause cancer in humans when used according to label directions.
Bayer has already set aside approximately $16 billion for Roundup-related legal costs, with the new settlement coming in addition to that amount. The agreement is intended to address most remaining claims, including future diagnoses among people exposed to Roundup before the settlement was proposed in February.
The company has also removed glyphosate from newer Roundup products sold for residential use, although glyphosate-based products remain available for agricultural markets.
The settlement could still face an appeal. Its approval marks a significant development in Bayer’s effort to contain the litigation, but it does not resolve the broader scientific debate over glyphosate or end all potential legal challenges.
Comments
No comments yet. Be the first to share your thoughts.